| scholarly article | Q13442814 |
| P50 | author | Louise J Barber | Q57334442 |
| Marco Gerlinger | Q30347474 | ||
| Andrea Sottoriva | Q39031024 | ||
| P2093 | author name string | Matthew Ashenden | |
| Matthew N Davies | |||
| Kamil A Lipinski | |||
| P2860 | cites work | Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. | Q51752412 |
| The genetic origin of drug resistance in neoplasms: implications for systemic therapy. | Q52688528 | ||
| Chromatin organization is a major influence on regional mutation rates in human cancer cells. | Q52837652 | ||
| Continuous clonal labeling reveals small numbers of functional stem cells in intestinal crypts and adenomas. | Q53090286 | ||
| Defining stem cell dynamics in models of intestinal tumor initiation. | Q53130842 | ||
| Does the cell number 10(9) still really fit one gram of tumor tissue? | Q53419525 | ||
| The fate of competing beneficial mutations in an asexual population. | Q54262235 | ||
| Acquired resistance to crizotinib from a mutation in CD74-ROS1. | Q54408281 | ||
| Fighting overtreatment in adjuvant breast cancer therapy | Q59616778 | ||
| Evolutionary dynamics of cancer in response to targeted combination therapy | Q21128788 | ||
| Quantifying the adaptive potential of an antibiotic resistance enzyme | Q21563371 | ||
| Historical contingency and the evolution of a key innovation in an experimental population of Escherichia coli | Q22066316 | ||
| Mutational processes molding the genomes of 21 breast cancers | Q24620915 | ||
| Distant metastasis occurs late during the genetic evolution of pancreatic cancer | Q24624284 | ||
| Massive genomic rearrangement acquired in a single catastrophic event during cancer development | Q24631164 | ||
| Acquired Resistance to Crizotinib from a Mutation in CD74 – ROS1 | Q27678436 | ||
| Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers | Q27852116 | ||
| Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor | Q27853093 | ||
| Rociletinib in EGFR-mutated non-small-cell lung cancer | Q27853159 | ||
| Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing | Q27860948 | ||
| Hypermutation in human cancer genomes: footprints and mechanisms | Q28255066 | ||
| Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers | Q28256331 | ||
| Microsatellites: simple sequences with complex evolution | Q28262642 | ||
| The clonal evolution of tumor cell populations | Q28271546 | ||
| Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance | Q28282963 | ||
| Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer | Q28308193 | ||
| High-throughput sequencing technologies | Q28647379 | ||
| Cancer in light of experimental evolution | Q28727500 | ||
| The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers | Q29395525 | ||
| Signatures of mutational processes in human cancer | Q29547191 | ||
| The cancer genome | Q29547643 | ||
| Systematic identification of genomic markers of drug sensitivity in cancer cells | Q29547695 | ||
| The life history of 21 breast cancers | Q29614642 | ||
| Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia | Q29615030 | ||
| Detection of circulating tumor DNA in early- and late-stage human malignancies | Q29615778 | ||
| Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours | Q29618396 | ||
| Advances in understanding cancer genomes through second-generation sequencing | Q30014827 | ||
| Generation of trisomies in cancer cells by multipolar mitosis and incomplete cytokinesis | Q30497558 | ||
| Single-molecule genomic data delineate patient-specific tumor profiles and cancer stem cell organization | Q30574447 | ||
| Image-aided estimate of tumor burden in Hodgkin's disease: evidence of its primary prognostic importance. | Q32073436 | ||
| Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. | Q33178852 | ||
| An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. | Q33590850 | ||
| Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. | Q33725972 | ||
| Beneficial mutations and the dynamics of adaptation in asexual populations. | Q33856627 | ||
| Clonal evolution in breast cancer revealed by single nucleus genome sequencing. | Q34041603 | ||
| Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis | Q34043392 | ||
| Analysis of the copy number profiles of several tumor samples from the same patient reveals the successive steps in tumorigenesis | Q34080289 | ||
| Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. | Q34116750 | ||
| Pervasive genetic hitchhiking and clonal interference in forty evolving yeast populations | Q34358875 | ||
| ALK inhibitors in non-small cell lung cancer: crizotinib and beyond | Q34431889 | ||
| Spatial and temporal diversity in genomic instability processes defines lung cancer evolution | Q34442770 | ||
| The architecture and evolution of cancer neochromosomes | Q34454339 | ||
| Timing and heterogeneity of mutations associated with drug resistance in metastatic cancers | Q34525966 | ||
| Tolerance of whole-genome doubling propagates chromosomal instability and accelerates cancer genome evolution. | Q34946877 | ||
| From fitness landscapes to seascapes: non-equilibrium dynamics of selection and adaptation. | Q34949551 | ||
| Paradoxical relationship between chromosomal instability and survival outcome in cancer | Q34988001 | ||
| Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia | Q34997508 | ||
| A functional landscape of resistance to ALK inhibition in lung cancer | Q35438912 | ||
| Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers | Q35540073 | ||
| The evolutionary history of lethal metastatic prostate cancer | Q35548366 | ||
| Tumor clone dynamics in lethal prostate cancer | Q35575930 | ||
| Studying clonal dynamics in response to cancer therapy using high-complexity barcoding. | Q35596310 | ||
| Evidence for multiple adaptive peaks from populations of bacteria evolving in a structured habitat | Q35760235 | ||
| APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity | Q35836909 | ||
| Subclonal diversification of primary breast cancer revealed by multiregion sequencing | Q35847434 | ||
| A Big Bang model of human colorectal tumor growth | Q36074227 | ||
| The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies | Q36104980 | ||
| Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing | Q36256943 | ||
| Effect of mutation order on myeloproliferative neoplasms | Q36320344 | ||
| Predictability of evolution depends nonmonotonically on population size | Q36535179 | ||
| Evolution and impact of subclonal mutations in chronic lymphocytic leukemia | Q36619124 | ||
| Impact of deleterious passenger mutations on cancer progression | Q36637272 | ||
| Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. | Q36673354 | ||
| Molecular and genetic properties of tumors associated with local immune cytolytic activity | Q36869059 | ||
| Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. | Q36892577 | ||
| Lineage tracing reveals multipotent stem cells maintain human adenomas and the pattern of clonal expansion in tumor evolution. | Q36991078 | ||
| Exploiting ecological principles to better understand cancer progression and treatment. | Q37561441 | ||
| Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy | Q37606223 | ||
| Genomic medicine frontier in human solid tumors: prospects and challenges | Q38099305 | ||
| Universality and predictability in molecular quantitative genetics. | Q38167547 | ||
| Empirical fitness landscapes and the predictability of evolution | Q38218962 | ||
| Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas | Q38245208 | ||
| Cancer: evolution within a lifetime | Q38257835 | ||
| Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution | Q38257912 | ||
| Dissecting cancer evolution at the macro-heterogeneity and micro-heterogeneity scale. | Q38305991 | ||
| Mapping spatial heterogeneity in the tumor microenvironment: a new era for digital pathology. | Q38323254 | ||
| A spatial model predicts that dispersal and cell turnover limit intratumour heterogeneity | Q38843089 | ||
| Prospective derivation of a living organoid biobank of colorectal cancer patients. | Q38877277 | ||
| Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor | Q38880070 | ||
| Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy | Q40224084 | ||
| Quantitative evolutionary dynamics using high-resolution lineage tracking | Q40499709 | ||
| Tracking the clonal origin of lethal prostate cancer | Q41762568 | ||
| The effect of one additional driver mutation on tumor progression. | Q41846748 | ||
| Deterministic and stochastic regimes of asexual evolution on rugged fitness landscapes | Q42041571 | ||
| Human mutation rate associated with DNA replication timing | Q42085559 | ||
| Cancer stem cells as 'units of selection'. | Q42108136 | ||
| Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. | Q42183079 | ||
| APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development | Q42213577 | ||
| Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing | Q43118556 | ||
| Tumor burden is predictive of survival in patients with non-small-cell lung cancer and with activating epidermal growth factor receptor mutations who receive gefitinib | Q43795365 | ||
| Genetic variegation of clonal architecture and propagating cells in leukaemia | Q44426152 | ||
| The molecular diversity of adaptive convergence. | Q46185374 | ||
| Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression | Q46470629 | ||
| Acquired resistance to crizotinib from a mutation in CD74-ROS1. | Q46932181 | ||
| Whole-genome characterization of chemoresistant ovarian cancer | Q50272478 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 49-63 | |
| P577 | publication date | 2016-01-01 | |
| P1433 | published in | Trends in cancer | Q27726777 |
| P1476 | title | Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine | |
| P478 | volume | 2 |
| Q94526140 | A Preliminary Study of CT Texture Analysis for Characterizing Epithelial Tumors of the Parotid Gland |
| Q36125108 | A novel method for RNA extraction from FFPE samples reveals significant differences in biomarker expression between orthotopic and subcutaneous pancreatic cancer patient-derived xenografts |
| Q97652732 | A somatic evolutionary model of the dynamics of aneuploid cells during hematopoietic reconstitution |
| Q38767006 | ALK gene alterations in cancer: biological aspects and therapeutic implications |
| Q55314165 | Addressing the challenges of applying precision oncology. |
| Q64245159 | An Integrative Systems Biology and Experimental Approach Identifies Convergence of Epithelial Plasticity, Metabolism, and Autophagy to Promote Chemoresistance |
| Q48115878 | An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer. |
| Q100558888 | An enhanced genetic model of relapsed IGH-translocated multiple myeloma evolutionary dynamics |
| Q89565938 | Blockade of TLR4 using TAK-242 (resatorvid) enhances anti-cancer effects of chemotherapeutic agents: a novel synergistic approach for breast and ovarian cancers |
| Q89676789 | Cancer (r)evolution |
| Q47313036 | Cancer Progression Models and Fitness Landscapes: a Many-to-Many Relationship |
| Q93043617 | Cancer-Associated Mutations but No Cancer: Insights into the Early Steps of Carcinogenesis and Implications for Early Cancer Detection |
| Q50908461 | Changing mutational and adaptive landscapes and the genesis of cancer. |
| Q50545407 | Citrullinated α-enolase is an effective target for anti-cancer immunity. |
| Q45067426 | Classifying the evolutionary and ecological features of neoplasms |
| Q52594128 | Clinicopathological analysis of polyploid diffuse large B-cell lymphoma. |
| Q38943125 | Clonal cooperativity in heterogenous cancers |
| Q41315076 | Clonal evolution of chemotherapy-resistant urothelial carcinoma. |
| Q91752428 | Clonal evolution through genetic bottlenecks and telomere attrition: Potential threats to in vitro data reproducibility |
| Q38703541 | Computational Methods for Characterizing Cancer Mutational Heterogeneity |
| Q58602209 | Criticality in tumor evolution and clinical outcome |
| Q55054189 | Cutaneous Papillomaviruses and Non-melanoma Skin Cancer: Causal Agents or Innocent Bystanders? |
| Q53834599 | DNA methylation profiling opens a new phase in the search of targeted therapy against Ewing sarcoma. |
| Q92296014 | Detailed modeling of positive selection improves detection of cancer driver genes |
| Q91254556 | Detecting repeated cancer evolution from multi-region tumor sequencing data |
| Q88513872 | Development versus Evolution in Cancer Biology |
| Q37397222 | Differential selective pressure alters rate of drug resistance acquisition in heterogeneous tumor populations |
| Q63966653 | Diffusion weighted MRI as an early predictor of tumor response to hypofractionated stereotactic boost for prostate cancer |
| Q90064873 | Estimating the predictability of cancer evolution |
| Q92367961 | Every which way? On predicting tumor evolution using cancer progression models |
| Q58802587 | Exploiting vulnerabilities in cancer signalling networks to combat targeted therapy resistance |
| Q92711548 | Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancer |
| Q89882693 | Genetic heterogeneity and evolutionary history of high-grade ovarian carcinoma and matched distant metastases |
| Q90083261 | Genetic heterogeneity within collective invasion packs drives leader and follower cell phenotypes |
| Q36192083 | Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma |
| Q38910371 | Homeostasis Back and Forth: An Ecoevolutionary Perspective of Cancer |
| Q61796801 | Imbalanced sphingolipid signaling is maintained as a core proponent of a cancerous phenotype in spite of metabolic pressure and epigenetic drift |
| Q91949609 | Improving the diagnosis of common parotid tumors via the combination of CT image biomarkers and clinical parameters |
| Q93122680 | Life and death of circulating cell-free DNA |
| Q38980681 | Measuring cancer evolution from the genome. |
| Q89882131 | Measuring single cell divisions in human tissues from multi-region sequencing data |
| Q49546284 | Metastasis seeding cells: Lone invaders or mass migrators? |
| Q49918002 | Mitochondrial Metabolism: Yin and Yang for Tumor Progression |
| Q39441390 | Mouse versus Human Neutrophils in Cancer: A Major Knowledge Gap. |
| Q48013951 | Multilevel, Dynamic Chronic Obstructive Pulmonary Disease Heterogeneity. A Challenge for Personalized Medicine |
| Q103806007 | Mutation-selection balance and compensatory mechanisms in tumour evolution |
| Q54295384 | Predicting evolution. |
| Q92116009 | Prognostic significance of an invasive leader cell-derived mutation cluster on chromosome 16q |
| Q47425176 | Progress and challenges of sequencing and analyzing circulating tumor cells |
| Q33594692 | Rational design of non-resistant targeted cancer therapies |
| Q28070120 | Recent advances in the biology of human circulating tumour cells and metastasis |
| Q58105771 | Reply to 'Currently available bulk sequencing data do not necessarily support a model of neutral tumor evolution' |
| Q41710165 | Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf-/- mouse model. |
| Q92659402 | Resolving genetic heterogeneity in cancer |
| Q91968324 | SREBP1-dependent de novo fatty acid synthesis gene expression is elevated in malignant melanoma and represents a cellular survival trait |
| Q28597478 | Should tissue structure suppress or amplify selection to minimize cancer risk? |
| Q42087584 | Simultaneous evolutionary expansion and constraint of genomic heterogeneity in multifocal lung cancer |
| Q90356949 | Somatic selection distinguishes oncogenes and tumor suppressor genes |
| Q89640448 | The application of single-cell sequencing technology in the diagnosis and treatment of hepatocellular carcinoma |
| Q58562952 | The burden of cancer in Spain |
| Q64263344 | The impact of proliferation-migration tradeoffs on phenotypic evolution in cancer |
| Q98613082 | The special issue on cancer and evolution: Lessons learned |
| Q64957287 | Therapeutic bronchoscopy in the era of genotype directed lung cancer management. |
| Q50128372 | Transcriptome evolution from breast epithelial cells to basal-like tumors. |
| Q88548676 | Treatment resistance in urothelial carcinoma: an evolutionary perspective |
| Q89866606 | Tumour heterogeneity and the evolutionary trade-offs of cancer |
| Q98613071 | When, why and how tumour clonal diversity predicts survival |
Search more.